探讨孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗哮喘的临床效果

Investigate the Clinical Effect of Montelukast Sodium Combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation in the Treatment of Asthma

目的研究孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗哮喘的临床效果。方法选取我院2017年10月至2018年10月收治的96例哮喘患者为研究对象,按照盲抽法将其分为相同的两组,即对照组和研究组各48例。对照组患者采取孟鲁司特钠治疗,研究组采取孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗。比较两组患者治疗前后的肺功能指标。结果对照组患者与研究组患者在治疗前的呼气流量峰值与用力肺活量相比,P>0.05,差异不具有统计学意义。在治疗后,对照组患者的呼气流量峰值为(4.62±0.24)L/s,明显低于研究组患者的呼气流量峰值(5.31±0.26)L/s,P<0.05,差异具有统计学意义。对照组患者在治疗后的用力肺活量为(2.67±0.49)L,明显低于研究组患者的用力肺活量(2.98±0.46)L,P<0.05,差异具有统计学意义。结论孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗哮喘患者,可以显著地改善患者的肺功能指标,提高患者的生活质量。

Objective To study the clinical effect of Montelukast Sodium combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation in the treatment of asthma.Methods A total of 96 asthma patients admitted to our hospital from October 2017 to October 2018 were enrolled in the study.They were divided into the same two groups according to the blind pumping method,namely 48 cases in the control group and 48 cases in the study group.Patients in the control group were treated with Montelukast Sodium,and the study group was treated with Montelukast Sodium combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation.The lung function indexes of the two groups before and after treatment were compared.Results The peak expiratory flow before treatment and the patients in the study group were compared with the forced vital capacity(P>0.05).The difference was not statistically significant.After treatment,the peak expiratory flow of the control group was(4.62±0.24)L/s,which was significantly lower than the peak expiratory flow of the study patients(5.31±0.26)L/s,P<0.05,the difference was statistically significant.The forced vital capacity of the control group after treatment was(2.67±0.49)L,which was significantly lower than the forced vital capacity of the study group(2.98±0.46)L,P<0.05,the difference was statistically significant.Conclusion Montelukast sodium combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation in the treatment of asthma patients can significantly improve the patient’s lung function indicators and improve the quality of life of patients.